Application of CRISPR-Cas9 based gene editing to study the pathogenesis of colon and liver cancer using organoids

被引:15
|
作者
Ramakrishna, Gayatri [1 ]
Babu, Preedia E. [1 ]
Singh, Ravinder [1 ]
Trehanpati, Nirupma [1 ]
机构
[1] Inst Liver & Biliary Sci, Dept Mol & Cellular Med, D1 Block, Delhi 110070, India
关键词
Organoids; CRISPR-Cas9; Cancer; Liver; Colon; STEM-CELLS; SEQUENCES; CAS;
D O I
10.1007/s12072-021-10237-z
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Two breakthrough techniques that have totally revolutionized biology in last 1 decade are the discovery of genome editing tools and growing the stem cells/primary tissue explants in defined 3D culture. In this regard the discovery of CRISPR-Cas9 as a specific gene editing tool and organoid culture from adult stem cell has provided easy handy tools to uncover the process of organ development and also modeling cancer. Genetically modified organoids have been developed by sequential knockout and knockin of driver mutations by genome editing followed by niche-based selection. The modified organoids when xenotransplanted in animal models faithfully recapitulate the neoplastic events of human tumors. The present review focuses on the merging of these two powerful technologies in understanding the complexities of colon and liver cancer.
引用
收藏
页码:1309 / 1317
页数:9
相关论文
共 50 条
  • [1] Application of CRISPR-Cas9 based gene editing to study the pathogenesis of colon and liver cancer using organoids
    Gayatri Ramakrishna
    Preedia E. Babu
    Ravinder Singh
    Nirupma Trehanpati
    Hepatology International, 2021, 15 : 1309 - 1317
  • [2] Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer
    Meng, Hui
    Nan, Manman
    Li, Yizhen
    Ding, Yi
    Yin, Yuhui
    Zhang, Mingzhi
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [3] Application of CRISPR-Cas9 gene editing to treat HBV
    Yan, Kun
    Feng, Jiangpeng
    Xiong, Yong
    Chen, Yu
    CHINESE SCIENCE BULLETIN-CHINESE, 2019, 64 (30): : 3142 - 3150
  • [4] Gene editing for the treatment of lung cancer (CRISPR-Cas9)
    Castillo, Andres
    COLOMBIA MEDICA, 2016, 47 (04): : 178 - 180
  • [5] Controlling CRISPR-Cas9 Gene Editing
    Dowdy, Steven F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (03): : 289 - 290
  • [6] Introduction to CRISPR-Cas9 Gene Editing
    Mason, J. M.
    BIRTH DEFECTS RESEARCH, 2020, 112 (11): : 809 - 809
  • [7] Gene editing strategy for alpha-1 antitrypsin deficiency through CRISPR-cas9 in liver organoids
    Perez-Luz, Sara
    Gomez-Mariano, Gema
    Perez de Castro, Ignacio
    Justo, Iago
    Marcacuzco, Alberto
    Hierro, Loreto
    Garfia, Cristina
    Martinez-Delgado, Beatriz
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (SUPPL 1) : 463 - 463
  • [8] Application of CRISPR-Cas9 gene editing for congenital heart disease
    Seok, Heeyoung
    Deng, Rui
    Cowan, Douglas B.
    Wang, Da-Zhi
    CLINICAL AND EXPERIMENTAL PEDIATRICS, 2021, 64 (06) : 269 - 279
  • [9] Modelling the Cancer Phenotype in the Era of CRISPR-Cas9 Gene Editing
    Stewart, J.
    Banerjee, S.
    Pettitt, S. J.
    Lord, C. J.
    CLINICAL ONCOLOGY, 2020, 32 (02) : 69 - 74
  • [10] The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy
    Wu, Hong-yan
    Cao, Chun-yu
    BRIEFINGS IN FUNCTIONAL GENOMICS, 2019, 18 (02) : 129 - 132